Pieter C Smits

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up
    Pieter C Smits
    Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 42:2063-9. 2003
  2. ncbi request reprint Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: an observational study
    Francesco Saia
    Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 61:455-60. 2004
  3. ncbi request reprint Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study
    Francesco Saia
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Circulation 108:1927-9. 2003
  4. ncbi request reprint Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RES
    Marco Valgimigli
    Erasmus Medical Center, Rotterdam, The Netherlands
    Circulation 111:1383-9. 2005
  5. doi request reprint Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography
    Josep Gomez-Lara
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:1271-80. 2011
  6. ncbi request reprint Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings
    Kengo Tanabe
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Cardiol 94:115-8. 2004
  7. ncbi request reprint Effectiveness of sirolimus-eluting stent implantation for the treatment of coronary artery disease in octogenarians
    Maniyal Vijayakumar
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 94:909-13. 2004
  8. ncbi request reprint Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery
    Angela Hoye
    Department of Cardiology, Thoraxcenter, Erasmus Medical Centre, Rotterdam, The Netherlands
    Coron Artery Dis 15:171-5. 2004
  9. doi request reprint Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial
    Salvatore Brugaletta
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:1281-9. 2011
  10. ncbi request reprint Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: one-year clinical outcomes of 99 consecutive patients--the Rotterdam experience
    Chourmouzios A Arampatzis
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 63:57-60. 2004

Detail Information

Publications53

  1. ncbi request reprint Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up
    Pieter C Smits
    Department of Cardiology, Thorax Center, Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 42:2063-9. 2003
    ..We report on the procedural and six-month results of the first percutaneous and stand-alone study on myocardial repair with autologous skeletal myoblasts...
  2. ncbi request reprint Clinical and angiographic outcomes after overdilatation of undersized sirolimus-eluting stents with largely oversized balloons: an observational study
    Francesco Saia
    Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 61:455-60. 2004
    ..13 +/- 0.34 and restenosis rate was 7.7%. Although not routinely recommended in every patient, SES postdilatation with largely oversized balloons appears a safe and effective strategy for selected patients...
  3. ncbi request reprint Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study
    Francesco Saia
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Circulation 108:1927-9. 2003
    ..Sirolimus-eluting stents (SES) have recently been proven to reduce restenosis and reintervention compared with bare stents. Safety and effectiveness of SES in acute myocardial infarction remain unknown...
  4. ncbi request reprint Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RES
    Marco Valgimigli
    Erasmus Medical Center, Rotterdam, The Netherlands
    Circulation 111:1383-9. 2005
    ..The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown...
  5. doi request reprint Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography
    Josep Gomez-Lara
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:1271-80. 2011
    ..This study sought to compare the neointimal response of metallic everolimus drug-eluting stents (DES) and polymeric everolimus bioresorbable vascular scaffolds (BVS) by optical coherence tomography at 1 year...
  6. ncbi request reprint Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings
    Kengo Tanabe
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Cardiol 94:115-8. 2004
    ..At 6 months, the incidence of major adverse cardiac events was 10.3% (1 death and 5 target lesion revascularizations) with no episodes of acute myocardial infarction or stent thrombosis...
  7. ncbi request reprint Effectiveness of sirolimus-eluting stent implantation for the treatment of coronary artery disease in octogenarians
    Maniyal Vijayakumar
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 94:909-13. 2004
    ..SES implantation in octogenarians appears to be feasible and is associated with very small subsequent need for repeat target vessel revascularization at 1 year...
  8. ncbi request reprint Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery
    Angela Hoye
    Department of Cardiology, Thoraxcenter, Erasmus Medical Centre, Rotterdam, The Netherlands
    Coron Artery Dis 15:171-5. 2004
    ..We evaluated the impact of utilizing the sirolimus-eluting stent (SES) in this high-risk population...
  9. doi request reprint Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial
    Salvatore Brugaletta
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:1281-9. 2011
    ..This study sought to investigate quantitative and homogeneity differential echogenicity changes of the ABSORB scaffold (1.1) during the first year after implantation...
  10. ncbi request reprint Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: one-year clinical outcomes of 99 consecutive patients--the Rotterdam experience
    Chourmouzios A Arampatzis
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 63:57-60. 2004
    ..6%. SES implantation for multivessel disease in a consecutive series of patients is associated with low incidence of adverse events. The reported results are related predominantly to the reduction in repeat revascularization...
  11. ncbi request reprint Sirolimus-eluting stents for the treatment of atherosclerotic ostial lesions
    Maniyal Vijayakumar
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    J Invasive Cardiol 17:10-2. 2005
    ..Various stent designs have failed to show significant improvement in target lesion revascularization (TLR) rates. The present study evaluates the clinical outcomes following sirolimus-eluting stent implantation for ostial lesions...
  12. ncbi request reprint Very long sirolimus-eluting stent implantation for de novo coronary lesions
    Muzaffer Degertekin
    Department of Interventional Cardiology, Thoraxcentre, Erasmus MC, Rotterdam, The Netherlands
    Am J Cardiol 93:826-9. 2004
    ..1%), and the overall incidence of major cardiac events was 8.3%. Thus, SES implantation appears safe and effective for de novo coronary lesions requiring multiple stent placement over a very long vessel segment...
  13. ncbi request reprint Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease
    Angela Hoye
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    J Invasive Cardiol 16:230-3. 2004
    ..Increased utilization of distal protection devices might reduce the peri-procedural rate of AMI...
  14. ncbi request reprint The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease
    Ron T van Domburg
    Thoraxcenter, room H 539, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur Heart J 26:675-81. 2005
    ..Therefore, we investigated the impact of SES on the clinical practice of CABG and PCI in a series of unselected consecutive patients...
  15. ncbi request reprint Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions
    Angela Hoye
    Department of Interventional Cardiology, Erasmus MC, Rotterdam, The Netherlands
    J Am Coll Cardiol 43:1954-8. 2004
    ..The aim of this study was to assess sirolimus-eluting stent (SES) implantation for the treatment of chronic total coronary occlusions (CTO)...
  16. ncbi request reprint Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry)
    Pedro A Lemos
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Am J Cardiol 93:633-6. 2004
    ..7% versus 3.9%, respectively (p = 0.1). The 12-month target lesion revascularization rate was 5.5%. In conclusion, 2.25-mm SESs were associated with low rates of clinical and angiographic late complications...
  17. ncbi request reprint Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome
    Chourmouzios A Arampatzis
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 62:292-6; discussion 297. 2004
    ..04 +/- 0.65 mm and one focal restenosis (8% of patients). Elective SES implantation for LM disease was associated with zero mortality and a very low incidence of additional major adverse events at 1 year...
  18. ncbi request reprint Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study
    Pedro A Lemos
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Circulation 109:1366-70. 2004
    ..The factors associated with the occurrence of restenosis after sirolimus-eluting stent (SES) implantation in complex cases are currently unknown...
  19. ncbi request reprint Effectiveness of sirolimus-Eluting stent implantation for coronary narrowings <50% in diameter
    Angela Hoye
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 94:112-4. 2004
    ..At a mean follow-up of 399 +/- 120 days, the survival-free of major adverse events was 95%, with no patient requiring target lesion revascularization...
  20. doi request reprint Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease
    Cihan Simsek
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center Rotterdam, Dr Molewaterplein 40, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 76:41-9. 2010
    ..There are limited data on the long-term safety and efficacy profile of coronary stent implantation in patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI)...
  21. ncbi request reprint Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases
    Pedro A Lemos
    Erasmus Medical Center, Thoraxcenter, Bd 406, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Circulation 108:257-60. 2003
    ..We describe the clinical and morphological patterns of restenosis after sirolimus-eluting stent (SES) implantation...
  22. ncbi request reprint Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry
    Pedro A Lemos
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Circulation 109:190-5. 2004
    ..The effectiveness of sirolimus-eluting stents in unselected patients treated in the daily practice is currently unknown...
  23. doi request reprint Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therap
    Salvatore Brugaletta
    Interventional Cardiology Department, Thoraxcenter, Erasmus MC, s Gravendijkwal 230, Rotterdam, The Netherlands
    Eur Heart J 33:1325-33. 2012
    ..Recovery of a normal endothelial-dependent vasomotion may be enabled by scaffold bioresorption, composition of the underlying tissue, or a combination of both mechanisms...
  24. doi request reprint Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man
    Bill D Gogas
    Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 5:656-65. 2012
    ..This study sought to investigate in vivo the vascular response at the proximal and distal edges of the second-generation ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS)...
  25. ncbi request reprint Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease
    Chourmouzios A Arampatzis
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Cardiol 92:327-9. 2003
    ..The implantation of this stent was associated with abolition of post-discharge fatal events and percutaneous reintervention...
  26. doi request reprint Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes
    Patrick W Serruys
    Thorax Center, Erasmus Medical Center, Gravendijkwal 230, Rotterdam, The Netherlands
    J Am Coll Cardiol 58:1578-88. 2011
    ..The aim of this study was to demonstrate that the prevention of early scaffold area shrinkage of the ABSORB BVS (Rev.1.1, Abbott Vascular, Santa Clara, California) was sustained and not simply delayed by a few months...
  27. ncbi request reprint Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis
    Francesco Saia
    Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands
    Catheter Cardiovasc Interv 62:283-8. 2004
    ..1% VBT vs. 81.5% SES; P = 0.8 by log rank). The result of this nonrandomized study suggests that sirolimus-eluting stent implantation is at least as effective as vascular brachytherapy in the treatment of in-stent restenosis...
  28. ncbi request reprint Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction
    Pedro A Lemos
    Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands
    J Am Coll Cardiol 43:704-8. 2004
    ..This study investigated the clinical outcomes of patients with ST-segment elevation myocardial infarction (MI) treated with sirolimus-eluting stents (SESs) or with conventional bare stents...
  29. doi request reprint Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography
    Josep Gomez-Lara
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:992-1001. 2011
    ....
  30. ncbi request reprint Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry substudy
    Susanne S Pedersen
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 44:997-1001. 2004
    ..Type D patients experience increased negative emotions and tend not to express these emotions in social interactions...
  31. doi request reprint The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry
    Yoshinobu Onuma
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    J Am Coll Cardiol 54:269-76. 2009
    ....
  32. ncbi request reprint Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound
    Carlos A G van Mieghem
    Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    Circulation 114:645-53. 2006
    ..Multislice computed tomography (MSCT) is a promising technique for noninvasive coronary evaluation. We evaluated the diagnostic performance of high-resolution MSCT to detect ISR after stenting of the LMCA...
  33. ncbi request reprint Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance
    Pierfrancesco Agostoni
    Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands
    Am J Cardiol 95:644-7. 2005
    ..The use of intravascular ultrasound, used in 41% of the procedures, was not associated with additional clinical benefit with respect to angiographic-assisted stent deployment...
  34. doi request reprint Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial
    Elvin Kedhi
    Department of Cardiology, Maasstad Ziekenhuis, Rotterdam, The Netherlands
    EuroIntervention 7:1376-85. 2012
    ....
  35. ncbi request reprint Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure
    Elena Biagini
    Department of Cardiology, Thoraxcenter, Erasmus MC, Bd406, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Heart Fail 8:641-8. 2006
    ..There is experimental evidence that transplanting skeletal myoblasts (SM) into the post-infarction myocardial scar improves regional and global left ventricular (LV) function...
  36. ncbi request reprint Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops
    Paul Steendijk
    Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    Nat Clin Pract Cardiovasc Med 3:S94-100. 2006
    ..Our findings indicate hemodynamic improvement after follow-up for up to 1 year, which is especially promising in view of the expected decline in left ventricular function in these patients...
  37. doi request reprint Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up
    Josep Gomez-Lara
    Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 4:789-99. 2011
    ..The aim of this study was to compare the angiographic changes in coronary geometry of the bioresorbable vascular scaffolds (BVS) and metallic platform stent (MPS) between baseline and follow-up...
  38. doi request reprint Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy
    Caroline E Veltman
    Department of Cardiology, Erasmus University Medical Centre, Thoraxcentre, Room Ba 587, Erasmus MC, Gravendijkwal 230, PO Box 2040, 3015 CE Rotterdam, The Netherlands
    Eur Heart J 29:1386-96. 2008
    ..Secondary endpoints included mortality, NYHA class, N-terminal pro-B-natriuretic peptide levels, incidence of arrhythmias, and quality of life...
  39. doi request reprint A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents
    Josep Gomez-Lara
    Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
    JACC Cardiovasc Interv 3:1190-8. 2010
    ..The aim of this study was to assess the differences in terms of curvature and angulation of the treated vessel after the deployment of either a metallic stent or a polymeric scaffold device...
  40. doi request reprint 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent i
    Pieter C Smits
    Department of Cardiology, Maasstad Ziekenhuis, Groene Hilledijk 315, Rotterdam, The Netherlands
    J Am Coll Cardiol 58:11-8. 2011
    ....
  41. doi request reprint Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials
    Elvin Kedhi
    Maasstad Ziekenhuis, Rotterdam, The Netherlands
    EuroIntervention 8:599-606. 2012
    ....
  42. ncbi request reprint Collateral formation in patients after percutaneous myocardial revascularization: a mechanism for improvement?
    Chi Hang Lee
    Department of Cardiology, Erasmus Medical Center Rotterdam, The Netherlands
    J Invasive Cardiol 15:488-90. 2003
    ..Despite the symptomatic improvement documented in clinical trials, underlying mechanism remains unknown...
  43. doi request reprint Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes
    Patrick W Serruys
    Thoraxcenter, Ba 583, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Circulation 122:2301-12. 2010
    ..Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified...
  44. ncbi request reprint Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry
    Pedro A Lemos
    Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Dr Molewaterplein 40, NL 3015 GD Rotterdam, The Netherlands
    J Am Coll Cardiol 41:2093-9. 2003
    ..This study evaluated the early outcomes of patients with acute coronary syndromes (ACS) treated with sirolimus-eluting stents (SES)...
  45. ncbi request reprint Efficacy of percutaneous intramyocardial injections using a nonfluoroscopic 3-D mapping based catheter system
    Pieter C Smits
    Department of Cardiology, Thoraxcentre, University Hospital Rotterdam, The Netherlands
    Cardiovasc Drugs Ther 16:527-33. 2002
    ..Little is known about the efficacy of this drug delivery technique. We studied efficiency and retention of transendomyocardial injections with a NOGA guided injection catheter system by using scintigraphy with radio-labeled model drugs...
  46. doi request reprint Do we have a future with transcatheter adventitial delivery of stem cells?
    Alexander N Kharlamov
    Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cardiol 165:217-21. 2013
    ..Potentially, more advanced imaging provides a chance to deliver infusate to the adventitial layer, which is a gate to the vessel wall for inflammation as well as a source of stem and progenitor cells, and myofibroblasts...
  47. ncbi request reprint TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation
    Kengo Tanabe
    Division of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    Circulation 107:559-64. 2003
    ..We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR)...
  48. ncbi request reprint Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience
    Muzaffer Degertekin
    Thoraxcenter, University Hospital Rotterdam, The Netherlands
    J Am Coll Cardiol 41:184-9. 2003
    ..In this study, we assess the value of sirolimus eluting stent (SES) implantation in patients with complex in-stent restenosis (ISR)...
  49. ncbi request reprint Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy
    Francesco Saia
    Erasmus MC, Thoraxcenter, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Am J Cardiol 92:200-3. 2003
  50. ncbi request reprint Imaging of atherosclerosis. Remodelling of coronary arteries
    Gerard Pasterkamp
    Experimental Cardiology Laboratory, Heart Lung Institute, University Medical Center, ICIN, Utrecht
    J Cardiovasc Risk 9:229-35. 2002
    ..The mechanisms of arterial remodelling are poorly understood. This is mainly due to lack of good in vitro and animal models which makes mechanistic studies difficult...
  51. ncbi request reprint Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents
    Pedro A Lemos
    Heart Institute InCor, University of Sao Paulo Medical School, Sao Paulo, Brazil
    Am J Cardiol 95:167-72. 2005
    ..It seems unlikely that restenosis could be a contributing factor that influenced the increased mortality of patients who had impaired renal function...
  52. ncbi request reprint Predictors of survival after contemporary percutaneous coronary revascularization for acute myocardial infarction in the real world
    Chi Hang Lee
    Cardiac Department, National University Hospital, Level 3, Main Building 5, Lower Kent Ridge Road, Singapore, 119074
    J Invasive Cardiol 16:627-31. 2004
    ..Among patients with cardiogenic shock, similar mortality was observed in patients with anterior myocardial infarction (MI) or inferior MI with/without right ventricle involvement...
  53. ncbi request reprint Left ventricular apical ballooning
    Reza Alizadeh Dehnavi
    Vascular Medicine, Department of General Internal Medicine and Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands
    Int J Cardiovasc Imaging 22:327-31. 2006
    ..Here we present (to our knowledge) the first case of this syndrome in a negroid patient...